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 Pre-conditioning has emerged as a
potentially powerful means of reducing
ischemia-reperfusion injury.
 Several animal models have implicated
adenosine in pre-conditioning pathways,
but its role in human physiology is
unknown.
 In human volunteers, the authors
demonstrate that adenosine receptor
activation in “trigger” tissue is an important
step in initiating a pre-conditioning signal,
but adenosine receptor blockade in “target”
tissue does not block the protection
afforded by pre-conditioning.
 The authors also demonstrate that
pre-conditioning elaborates a transferrable
cardioprotective factor(s) into the serum.
This elaboration is prevented by adenosine
receptor blockade but can be mirrored by
the infusion of exogenous adenosine.
 An improved understanding of the
physiological effectors of pre-conditioning
may allow for better targeted clinical
studies of pre-conditioning and
pre-conditioning mimetics in the future.
ABBR EV I A T I ON S
AND ACRONYMS
Ach = acetylcholine
ANOVA = analysis of variance
FMD = ﬂow-mediated dilation
GTN = glyceryltrinitrate
IR = ischemia-reperfusion
LV = left ventricular
NMD = nitrate-mediated
dilation
rIPC = remote ischemic
pre-conditioning
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462SUMMARYDe
spit
or
Ci
stit
evi
t reRemote ischemic pre-conditioning (rIPC) has emerged as a potential mechanism to reduce ischemia-reperfusion
injury. Clinical data, however, have been mixed, and its physiological basis remains unclear, although it appears
to involve release of circulating factor(s) and/or neural pathways. Here, the authors demonstrate that
adenosine receptor activation is an important step in initiating human pre-conditioning; that pre-conditioning
liberates circulating cardioprotective factor(s); and that exogenous adenosine infusion is able to recapitulate
release of this factor. However, blockade of adenosine receptors in ischemic tissue does not block the
protection afforded by pre-conditioning. These data have important implications for deﬁning the physiology of
human pre-conditioning and its translation to future clinical trials. (J Am Coll Cardiol Basic Trans Science
2016;1:461–71) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).R emote ischemic pre-conditioning (rIPC)induces protection of central (target) organsfrom ischemia-reperfusion (IR) by brief
ischemia of peripheral (trigger) tissue (1,2). Limb
ischemia achieves rIPC in humans, and has been
tested with positive results in clinical studies (3–10).
However, other recent clinical studies also show
neutral effects (11–15), and better understanding of
the mechanisms of rIPC in humans may lead to maxi-
mization of its beneﬁts. The signaling pathway from
the trigger limb to target organs is poorly deﬁned,
but involves release of circulating factor(s) (16–23)
and neural pathways (19,24–26).
In preclinical animal models, adenosine antago-
nists inhibit cardiac rIPC induced by renal and
mesenteric ischemia (27,28). Furthermore, femoral
arterial (but not femoral vein) adenosine infusion pre-
conditioned rat hearts and was inhibited by femoral
nerve transection. In a rabbit model, femoral artery
(but not femoral vein) infusion of adenosine released
humoral cardioprotective factor(s) into the circula-
tion, which reduced infarct size when transferred to a
naive Langendorff heart (19). However, a more recent
porcine study suggests that adenosine is not involved
in rIPC (29). The role of the adenosine pathway in
human rIPC remains unknown but clearly warrants
further investigation.
The aims of this study were to address: 1) whether
adenosine receptor activation is involved in
human endothelial rIPC-induced by limb ischemia;partment of Cardiovascular Medicine, University of Oxford, O
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in the “trigger” or “target” phases of rIPC; 3) its
effects on release of circulating cardioprotective
factor(s); and 4) whether arterial infusion of adeno-
sine liberates release of a circulating cardioprotective
factor(s) in humans.
METHODS
Protocols were approved by the local research
ethics committee (refs 08/H0604/152, 09/H0604/118,
10/H0604/28).
EXPERIMENTAL METHODS. Venous occ lus ion
p lethysmography. Strain-gauge plethysmography
was used to measure forearm blood ﬂow as
described previously (30). For each study, the
brachial artery of the nondominant arm was cannu-
lated with a 27-gauge needle (Cooper’s Needle
Works, Birmingham, United Kingdom) under local
anesthesia (3 ml of 1% lignocaine). Drugs or normal
saline (sodium chloride 0.9% wt/vol) were infused
continuously at 1 ml/min. During recording periods,
the hands were excluded from the circulation by
inﬂation of wrist cuffs to 200 mm Hg. Responses to
both acetylcholine (Ach) (25, 50, and 100 nmol/min)
and glyceryltrinitrate (GTN) (4, 8, and 16 nmol/min)
were assessed before and after combined rIPC and
IR. All recordings and analysis were made using
LabChart v.6 (AD Instruments, Chalgrove, United
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463F low-mediated di lat ion . The brachial artery was
continuously imaged longitudinally just above the
level of the antecubital fossa and ﬂow-mediated
dilation (FMD) calculated as the maximum percent-
age change in the vessel diameter from baseline
following release of a distal pressure cuff after 5 min
of inﬂation (200 mm Hg) as previously described (31).
Vessel diameters were calculated using the automatic
B-mode edge detection software Brachial Analyzer for
Research (Medical Imaging Applications, Coralville,
Iowa). Following each FMD, 25 mg of GTN was given
sublingually and nitrate-mediated dilation (NMD)
assessed as a measure of endothelium-independent
vasorelaxation.
Induct ion of IR and r IPC. IR consisted of 20 min of
ischemia followed by 15-min reperfusion, and
rIPC consisted of 3 cycles of 5 min of ischemia and
5-min reperfusion of the contralateral arm, both
achieved by inﬂation of a proximal pressure cuff to
200 mm Hg (3,32).
Mouse langendorf f infarct ion b ioassay . Mice
received heparin (200 IU, i.p.; Sigma-Aldrich, St.
Louis, Missouri) and were anesthetized with pento-
barbital (60 mg/kg, i.p.; Ceva Sante Animale,
Libourne, France). Isolated hearts were mounted on
the Langendorff perfusion apparatus (Radnoti Tech-
nologies, Monrovia, California), and perfused under
nonrecirculating conditions at a constant pressure of
80 mm Hg with 37C Krebs–Henseleit buffer (con-
sisting of the following in mmol/l: NaCl 120.0,
NaHCO3 25.0, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2
2.5, EDTA 0.5, and glucose 15). The solution was
continuously gassed with 95% O2–5% CO2 (pH 7.4).
After 20-min stabilization, isolated hearts were
perfused for 30 min using dialysate, washed out for 5
min, and then subjected to 30 min of no-ﬂow global
ischemia followed by 60 min of reperfusion. The left
ventricular (LV) developed pressure was calculated as
the difference between the systolic and end-diastolic
LV pressures. After freezing, the heart was then sliced
into 1-mm slices from the apex to the base, and slices
were incubated in 1% 2,3,5-triphenyltetrazolium
chloride (pH 7.4) (Sigma-Aldrich) at 37C for 15 min.
All slices were then scanned on a ﬂat-bed digital
scanner and weighed. Infarct size was determined by
semiautomated computer planimetry (Image Pro
Analyzer v7.0, Bethesda, Maryland). Because this was
a model of global ischemia, the whole heart acts as
the “area at risk”, and infarct size is presented as a
percentage of whole-heart mass.
Product ion of d ia lysate to assay for c i r culat ing
card ioprotect ive factor (s ) . Heparinized whole
blood was centrifuged at 4,640 g and the plasma
fraction pipetted into a 15-kDa dialysis membrane andplaced in 20 volume of a modiﬁed KH buffer con-
taining (all in mmol/l) NaCl 118.5, KCL 4.7, KH2PO4
1.18, MgSO4 1.19, and D-glucose 11.0. After 48 h, the
dialysate solution was decanted and stored at 80C.
Before use, NaHCO3 25 mmol/l and CaCl2 2.4 mmol/l
was added to the buffer and saturated with 95% O2
and 5% CO2.
EXPERIMENTAL PROTOCOLS. Protocol 1 . Is adeno-
sine receptor activation involved in human rIPC
(Figure 1, upper panel)?
This was addressed in a randomized, parallel
group, double-blind placebo-controlled study utiliz-
ing the forearm model of combined rIPC/IR in healthy
volunteers. Systemic caffeine (4 mg/kg) (33) was used
as a pharmacological inhibitor of adenosine. Twenty
volunteers were randomized to infusion of caffeine
(n ¼ 10) or vehicle (normal [0.9%] saline) (n ¼ 10).
FMD was measured at baseline, after infusion of
caffeine or vehicle, and 15 min after reperfusion
following combined rIPC and forearm IR. Studies
were analyzed blinded to study group allocation. In 5
subjects, a control study was conducted to test the
effect of caffeine infusion on IR injury alone.
Protocol 2 . Is adenosine receptor activation
involved in the trigger and/or effector phase of
human rIPC, and does this inﬂuence release of the
circulating cardioprotective factor(s) (Figure 1, middle
and lower panels)?
This was addressed in a crossover design study of
11 male volunteers who underwent 2 studies sepa-
rated by 8 weeks. The human forearm model of rIPC/
IR was used. In this study, the brachial artery of the
upper limb being studied was directly infused with
caffeine 90 mg $ min1 per 100-ml forearm volume to
achieve a high local concentration of caffeine in the
study limb (34).
Study 1. The trigger phase was studied. The limb used
to generate rIPC was infused with caffeine. The
contralateral limb was subjected to IR, with mea-
surement of brachial artery FMD before ischemia and
15 min after reperfusion. In addition, venous blood
was drawn for producing dialysate and testing for the
presence of circulating cardioprotective factor(s)
before and after rIPC.
Study 2. The target phase was studied. The limb
used to generate the rIPC stimulus was not instru-
mented. The limb subjected to IR, was infused with
caffeine, with measurement of blood ﬂow responses
to Ach and GTN before ischemia and 15 min after
reperfusion. In addition, venous blood was drawn
for producing dialysate and testing for the presence
of a circulating cardioprotective factor(s) before and
after rIPC.
FIGURE 1 Protocols 1 and 2 Schematics
(Top) Protocol 1: ﬂow-mediated dilation (FMD) 1 measured at baseline, FMD 2 measured after infusion of caffeine (CAF) or placebo (PLAC).
Remote ischemic pre-conditioning (rIPC) is then delivered, and FMD 3 is measured after ischemia-reperfusion (IR). (Middle) Protocol 2:
Study 1. FMD 1 is measured before rIPC. Caffeine is infused into the trigger arm generating rIPC. FMD is measured after IR. (Bottom) Protocol 2:
Study 2. The target arm is infused with caffeine, and the dose response to acetylcholine (Ach) is measured. rIPC is delivered. Dose response to
ACh is measured after IR. GTN ¼ glyceryltrinitrate; NMD ¼ nitrate-mediated dilation.
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464Protocol 3 . Does arterial infusion of adenosine
liberate systemic release of a circulating car-
dioprotective factor(s) in humans?
This was addressed in a randomized dose-ranging
study in 20 nondiabetic patients with suspected or
known stable coronary disease undergoing coronary
angiography. Following diagnostic coronary angiog-
raphy, 75 ml of blood was withdrawn from a femoral
venous sheath into heparinized containers. Patients
were randomized in a 1:1 fashion to 1 of 2 doses of
adenosine (0.25 mg/kg or 0.75 mg/kg). An adenosine
solution (total volume 30 ml) was infused through
the femoral arterial sheath over 1 min with central
pressure monitoring and continuous electrocardio-
gram recording. Five minutes after the completion of
infusion, a second venous blood sample was taken.
Blood was used to produce dialysate, and car-
dioprotective efﬁcacy was tested in the murineLangendorff model as described in the preceding
text.
STATISTICAL ANALYSIS. Statistical testing was per-
formed using GraphPad Prism v5.03 (GraphPad Soft-
ware, La Jolla, California) or SAS version 9.2 (SAS
Institute, Cary, North Carolina). In protocol 1, analysis
of baseline, post-caffeine, and post-ischemia FMD
was by repeated measures analysis of variance
(ANOVA). In protocol 2 study 1, pre- and post-IR FMD
comparison was by paired t test, whereas in study 2,
pre- and post-ischemia dose-response curves in the
plethysmography protocol were compared using
2-way ANOVA with a post hoc Bonferroni multiple
comparison test. Analysis of infarct size (expressed as
percentage of LV) in the mouse Langendorff model
was by paired t test. Paired t tests were also used in
analysis of pre- and post-infusion caffeine levels. All
quoted values are the mean  SEM. A p value of <0.05
FIGURE 2 Serum Caffeine and Hemodynamic Indices
in Protocol 1
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465was considered statistically signiﬁcant. Sample sizes
for all studies were calculated using data from pre-
vious studies assuming a power of 80% with an a of
0.05. For the FMD studies, assuming a reduction from
8.0  4.0% to 3.5  2.0% post-IR, a sample size of 7
subjects in each group was calculated, and for the
plethysmography studies, assuming a reduction in
blood ﬂow response from 450  190% to 220  90% at
the top dose of Ach after IR, a sample size of 5 in each
group was calculated to show a difference.
RESULTS
PROTOCOL 1. Is adenosine receptor activation
involved in human rIPC?
All studies were analyzed blinded to study group
allocation. Demographic characteristics of groups
were similar, and caffeine did not increase blood
pressure, heart rate, or baseline brachial artery
diameter (Table 1, Figure 2). Baseline caffeine mea-
surements conﬁrmed that participants had adhered to
caffeine avoidance. Caffeine levels increased appro-
priately, conﬁrmed correct group allocations after
unblinding, and were comparable to previously
described values using this protocol (1.7 mmol/l to
20.0 mmol/l in the caffeine group and 3.0 mmol/l to 2.2
mmol/l in the placebo group). The protocol was well
tolerated by participants and was without sequelae.
Contro l exper iment : ef fec t of caf fe ine on
FMD and IR . Five participants underwent controlTABLE 1 Participant Demographics (Protocol 1)
Caffeine Group
(n ¼ 10)
Placebo Group
(n ¼ 10)
Age (yrs) 26.5  2.2 29.5  1.8
Male 7 5
Estimated caffeine
intake (mg/day)
210.0  72.5 231.0  80.4
Fasting glucose
(mmol/l)
5.0  0.2 5.2  0.2
BMI (kg/m2) 23.7  0.9 25.0  0.8
Baseline
MAP (mm Hg) 92.9  2.8 87.2  2.7
HR (beats/min) 66.0  4.3 67.0  2.3
Post-infusion
MAP (mm Hg) 91.8  3.0 86.5  2.7
HR (beats/min) 57.5  3.7 56.0  2.6
Brachial diameter (mm) 3.5  0.1 3.5  0.2
Caffeine pre (mmol/l) 1.7  0.5 3.0  0.7
Caffeine post (mmol/l) 20.0  1.2 2.2  0.6
Values are mean  SEM. There were no signiﬁcant differences in between group
demographic characteristics. Caffeine demonstrated a highly signiﬁcant rise in the
caffeine infusion group as expected (p < 0.0001 by paired t test).
BMI ¼ body mass index; HR ¼ heart rate; MAP ¼ mean arterial pressure.
Serum caffeine levels and hemodynamic changes. An expected
signiﬁcant increase was seen in systemic caffeine levels
following caffeine infusion from 1.7  0.5 to 20.3  1.2
(A) (p < 0.0001 by paired t test). This had no signiﬁcant effect
on the heart rate (B) or blood pressure (C) graph. Box and
whiskers represent the median and 5th and 95th percentiles,
respectively. Abbreviations as in Figure 1.
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466experiments to determine any effect of caffeine
on FMD or IR injury alone. Baseline FMD was 4.9 
0.85%, and following caffeine infusion, was 5.1 
0.57% (p > 0.05 by repeated measures ANOVA). After
IR, FMD was reduced to 0.8  0.22%, demonstrating a
signiﬁcant reduction from both baseline and post-
caffeine FMD (p ¼ 0.001) (Figure 3, upper panel, left-
hand graph). NMD was not signiﬁcantly affected by
either caffeine or IR injury (data not presented).
Placebo group (n ¼ 10). Baseline FMD was 6.2  1.3,
and this did not change signiﬁcantly after placebo
infusion to 5.2  0.4 (p ¼ 0.4). After combined
rIPC and IR, there was no signiﬁcant change in FMD
(5.4  1.2) in comparison with either the baseline or
post-infusion FMD, demonstrating the protective
effect of rIPC against IR injury (p ¼ 0.6) (Figure 3,
upper panel, middle graph).
Caffeine infusion (n ¼ 10). In the group receiving
caffeine (n ¼ 10) mean baseline FMD was 7.5  1.4, and
this did not change after caffeine (7.9  1.0; p ¼ 0.80).
However, after combined rIPC and IR, FMD decreased
signiﬁcantly to 3.5  1.4 (p ¼ 0.001), demonstrating
loss of the protective effect of rIPC by adenosine re-
ceptor blockade (p ¼ 0.0009 repeated measures
ANOVA) (Figure 3, upper panel, right-hand graph).
PROTOCOL 2. Is adenosine receptor activation
involved in the trigger and/or effector phase of hu-
man rIPC, and does this inﬂuence release of the
circulating cardioprotective factor(s)?
Participant demographic characteristics are listed
in Table 2. There was no signiﬁcant change in blood
pressure, heart rate, or baseline brachial artery
diameter with the infusion of caffeine into the
brachial artery. After infusion of caffeine, there was a
small, but statistically signiﬁcant, rise in systemic
caffeine levels (1.2  0.3 mmol/l to 2.6  0.3 mmol/l;
p ¼ 0.001), but with levels approximately 10-fold
lower than those observed following intravenous
caffeine infusion as in Protocol 1.
Study 1: Infus ion of caffeine into the tr igger arm.
FMD was 4.9  0.4 at baseline and reduced to
1.5  0.7 after combined rIPC and IR, demonstrating a
statistically signiﬁcant decrease in FMD in the pres-
ence of caffeine infusion in the arm triggering rIPC
(paired t test, p ¼ 0.01) (Figure 3, middle panel, left
graph), consistent with inhibition of the protective
effect of rIPC. There was no signiﬁcant change in
NMD throughout the study.
The effects of dialysate (produced from systemic
blood) on myocardial infarction demonstrated no
signiﬁcant difference in infarct size between dialy-
sate produced before or after rIPC (37.3  1.9
before and 34.25  2.0 after rIPC, n ¼ 10, pairedt test, p ¼ 0.31) (Figure 3, middle panel, right
graph), consistent with adenosine receptor blockade
inhibiting the release of the circulating car-
dioprotective factor(s).
Study 2 : Infus ion of caf fe ine into the target
arm. There was no signiﬁcant reduction in forearm
blood ﬂow in response to Ach after combined rIPC
and IR, consistent with ongoing protection by rIPC,
despite infusion of caffeine in the target organ (n ¼ 10,
2-way ANOVA, p ¼ 0.22) (Figure 3, lower panel, left
graph). There was no signiﬁcant change in NMD
throughout the study.
The effects of dialysate on myocardial infarction
demonstrated that there was a signiﬁcant difference
in infarct size between dialysate produced before or
after rIPC (47.8  2.4% whole heart before rIPC and
26.5  2.0% whole heart after rIPC, n ¼ 10, paired
t test, p ¼ 0.0001) (Figure 3, lower panel, right graph),
consistent with release of the circulating pre-
conditioning factor(s).
PROTOCOL 3. Does arterial infusion of adenosine
liberate systemic release of a circulating car-
dioprotective factor(s) in humans?
A total of 20 studies were conducted with 10 pa-
tients randomized to each group. Participant de-
mographic characteristics are listed in Table 3.
Arrhythmia and hemodynamic data . Adenosine
dose 0.25 mg/kg. There were no episodes of
arrhythmia noted. Mean arterial pressure dropped
from 96.8  6.6 mm Hg to 90.6  5.2 mm Hg at 30 s
and recovered rapidly to baseline values. Heart rate
increased from 66.8  2.8 beats/min to 80.4  4.4
beats/min at 60 s but decreased to 78.4  3.2 beats/
min at 80 s and had returned to baseline at 5 min.
Adenosine infusion was well tolerated, with no clin-
ically signiﬁcant side effects reported.
Adenosine dose 0.75 mg/kg. One patient had pre-
existing ﬁrst-degree heart block, which became
prolonged (without symptoms) before returning to
baseline. Episodes of 2:1 block were transient and
required no intervention. Mean arterial pressure
dropped from a mean of 92.9  3.0 mm Hg to 85.6
mm Hg at 60 s but recovered rapidly, with a mean
arterial pressure of 90.7  5.9 mm Hg recorded at
80 s. Heart rate increased from 62.2  2.3 beats/min
to 75.1  4.0 beats/min at 60 s and continued to
increase to 82.7  3.7 beats/min at 80 s before
returning to baseline at 5 min. Once more, the
adenosine infusion was well tolerated, with no
clinically signiﬁcant side effects reported.
Mur ine Langendorf f b ioassay data . Adenosine
0.25 mg/kg.Mean infarct size was 48.3  2.9% with
pre-infusion dialysate, which signiﬁcantly reduced
FIGURE 3 Adenosine Receptor Inhibition Abrogates rIPC Signal Generation
(Top) Protocol 1 results. Left shows the results from control studies showing that caffeine does not itself alter the response to rIPC/IR injury.Middle shows no signiﬁcant
change between FMD 1 and FMD 2. FMD 3 was not reduced, conﬁrming rIPC was effective in the placebo group. Right shows no signiﬁcant change between FMD 1
and FMD 2, conﬁrming that caffeine itself did not affect FMD. FMD 3 was signiﬁcantly reduced conﬁrming rIPC was inhibited in the caffeine group. (Middle) Protocol 2:
study 1 results. Left shows the signiﬁcant reduction in FMD responses after rIPC/IR with infusion of caffeine in the trigger arm. This conﬁrms inhibition of the protective
effect of rIPC. Right shows the effect of dialysate produced on myocardial infarction (MI) showing that there is no reduction in MI, suggesting that the observed
inhibition of rIPC is in part through reduction of release of a circulating factor(s). (Bottom) Protocol 2: study 2 results. Left shows no signiﬁcant reduction in response to
acetylcholine after rIPC and IR with infusion of caffeine in the target arm. This conﬁrms a protective effect of rIPC. Right shows the effect of dialysate produced on MI,
showing that there is a signiﬁcant reduction in MI, suggesting preserved release of circulating factor(s). Abbreviations as in Figure 1.
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TABLE 2 Participant Demographics (Protocol 2)
Study 1 Study 2
Age (yrs) 23.8  1.8
Est caff intake (mg/day) 186  54.4
Fasting Glc (mmol/l) 5.2  0.1 5.2  0.2
BMI (kg/m2) 23.4  0.7 23.6  0.6
Forearm vol. (cm3) 1,162  17.8
Baseline
MAP (mm Hg) 102.0  2.6 104.0  2.3
HR (beats/min) 58  2.8 56  2.4
Post-infusion
MAP (mm Hg) 105.8  3.5 104.8  1.6
HR (beats/min) 65.0  3.9 54.0  1.5
Caffeine pre (mmol/l) 1.3  0.3 1.3  0.4
Caffeine post (mmol/l) 2.2  0.3 2.6  0.3
Hemoglobin (g/dl) 15.8  0.4 15.9  0.3
Values are mean  SEM. In this crossover study, there were no signiﬁcant changes
seen in the 8 weeks between visits.
Abbreviations as in Table 1.
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468to 34.0  2.6% when hearts were perfused with
post-infusion dialysate (n ¼ 10 hearts, paired t test,
p ¼ 0.006) (Figure 4, left graph).
Adenosine 0.75 mg/kg.Mean infarct size was 47.1 
1.9% with pre-infusion dialysate, which signiﬁcantly
reduced to 35.7  2.1% when hearts were perfusedTABLE 3 Participant Demographics (Protocol 3)
0.25 mg/kg (n ¼ 10) 0.75 mg/kg (n ¼ 10)
Age (yrs) 60.4  4.1 61.9  2.4
Male 9 9
BMI (kg/m2) 28.0  1.1 25.9  1.1
Resting
MAP (mm Hg) 96.8  6.5 92.9  3.0
HR (beats/min) 66.8  2.8 62.2  2.3
Smoking status
Current or recent 3 (30) 1 (10)
Ex-smoker 3 (30) 4 (40)
Never 4 (40) 5 (50)
Hypertension 3 (30) 4 (40)
Family history 2 (20) 4 (40)
Previous MI 1 (10) 4 (40)
Statin use 6 (60) 9 (90)
ACE inhibitor use 4 (40) 4 (40)
Aspirin use 9 (90) 10 (100)
Coronary disease
No signiﬁcance (%) 4 (40) 1 (10)
1-vessel (%) 3 (30) 3 (30)
2-vessel (%) 2 (20) 4 (40)
3-vessel (%) 1 (10) 2 (20)
Values are mean  SEM or n (%). There were no signiﬁcant between-group
differences.
ACE ¼ angiotensin converting enzyme; MI ¼ myocardial infarction; other
abbreviations as in Table 1.with post-infusion dialysate (n ¼ 10, paired t test,
p ¼ 0.001) (Figure 4, right graph).
DISCUSSION
The novel ﬁndings from this study are as follows:
1) adenosine receptor activation is a mediator of
human remote pre-conditioning; 2) adenosine re-
ceptors are involved in the trigger phase of signaling;
3) adenosine receptors mediate rIPC in part through
release of circulating cardioprotective factor(s); and
4) pharmacological stimulation of arterial adenosine
receptors liberates a circulating cardioprotective fac-
tor(s). These ﬁndings have implications for the design
and interpretation of ongoing clinical studies in rIPC.
Importantly, we have identiﬁed a novel pathway that
liberates circulating cardioprotective factor(s), which
can be pharmacologically stimulated in humans.
In protocol 1, we delivered caffeine systemically
and this inhibited the protective effect of rIPC. In
protocol 2, we delivered the caffeine into the brachial
artery to achieve inhibition of adenosine receptors in
either the trigger or target limb. We demonstrate that
adenosine receptor inhibition in the trigger limb
blocks the induction of systemic rIPC and inhibits
release of circulating cardioprotective factor(s).
However, rIPC is preserved when caffeine is delivered
into the target organ, and release of the circulating
factor(s) after rIPC is also maintained. For methodo-
logical reasons, we used FMD to assess endothelial
responses of the contralateral arm when we infused
into the trigger arm, because we did not deem it
appropriate to cannulate both brachial arteries. We
used venous occlusion plethysmography when we
infused into the target tissue, because FMD cannot be
practically performed in this situation due to the
proximity of the ultrasound probe to the arterial
cannula and its impingement upon it. Caffeine has
been used to investigate pre-conditioning pathways
in humans previously (33).
Four nonhuman studies investigating kidney or
intestinal ischemia have reported that adenosine
receptor antagonists inhibit cardiac rIPC (27,35–37).
One study has shown no effect of adenosine antag-
onist on renal rIPC (38). The explanation for these
observations may relate to differential expression of
adenosine receptor subtypes in different tissues,
activation of differing signaling pathways such as
neurogenic or circulating factor(s) and/or species
differences. There are no data available regarding
human rIPC and adenosine, but our ﬁndings are
consistent with animal data showing that adenosine
receptor activation in the trigger organ is important
in rIPC. Whether adenosine receptor activation is
FIGURE 4 Exogenous Adenosine Releases a Circulating Cardioprotective Factor
Protocol 3 results. Left shows the effect of dialysate produced before and after 0.25 mg/kg adenosine on myocardial infarction (MI), showing
that there is a signiﬁcant reduction in MI, suggesting release of a circulating factor(s). Right shows similar results after infusion of 0.75 mg/kg
adenosine.
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469important in the target organ may depend upon the
target tissue, but in our study, it does not appear to
be important for human endothelial rIPC.
The nature of the circulating factor(s) that
contribute to rIPC is not known. Our group has shown
that rIPC liberates <15-kDa, hydrophobic, cross-
species factor(s) that can be dialyzed. In animals, it
can be released by peripheral nerve activation, arte-
rial adenosine infusion, or capsaicin, and its
release is inhibited in patients with diabetic neurop-
athy (19,39,40). We now show that activation of
arterial adenosine receptors liberates a circulating
cross-species cardioprotective factor(s) in humans.
Whether this factor(s) is itself important in mediating
the clinical effects of rIPC or a surrogate is not
known, but our ﬁndings raise the possibility to
investigate the biological and clinical effects of
pharmacological enhancement of the rIPC pheno-
type. Arterial adenosine has been used in one surgi-
cal study as a post-conditioning stimulus. Thirty
patients undergoing valve replacement received 1.5
mg/kg adenosine through the arterial aortic catheter
at the end of the operation (41). This was associated
with a transient nearly 30 mm Hg reduction in blood
pressure, but reduced troponin I release, lessened
inotrope requirement, and reduced intensive care
stay. With this study in mind, our experimental
protocol was designed to try and replicate the acti-
vation of a conditioning pathway using lower doses
of adenosine. If these cardioprotective effects could
be duplicated by lower doses with lesser side effects
in a peripheral artery, then this approach may have
more widespread applicability. Our data suggest thatlower doses in a peripheral artery are better tolerated
and may achieve biologically effective humoral car-
dioprotection. Indeed, this has relevance for future
work in the ﬁeld of rIPC and may eventually lead to
translation into clinical studies with testing during
cardiac surgery or even primary angioplasty for
myocardial infarction. Before this step, however,
further preclinical work is warranted to optimize
factors such as timing, dosage, and delivery route, as
well as to gain further data on potential clinical
effectiveness and safety.
STUDY LIMITATIONS. As with all studies using
competitive inhibitors, it is possible that off-target
effects of caffeine inﬂuence our results, but there
are currently no available adenosine receptor
subtype–speciﬁc antagonists for human use. It is
also true that our model is speciﬁc to human endo-
thelial rIPC rather than human cardiac rIPC, and
although we term the liberated factor(s) car-
dioprotective, it has only been demonstrated to truly
protect myocardium in experimental animal models,
and its effect on human myocardium in vivo is un-
known. However, further work is necessary in this
regard.
It should also be noted that the volunteers in our
studies in protocols 1 and 2 were young and free of
chronic health problems, and so as such, were not
representative of the more elderly individuals, with
multiple comorbidities and on medications, who
more typically present with coronary disease syn-
dromes, and in whom this intervention is most rele-
vant. Indeed, it may be that pre-conditioning in these
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: IR
injury is a common cause of cardiovascular morbidity and
mortality. Effectivemeans to reduce IRmay lead to large
clinical gains with activation of innate pre-conditioning
mechanisms potentially able to reduce infarct size by
50%. Currently, our understanding of the physiology of
pre-conditioning is incomplete, and clinical data are
mixed. Here, we demonstrate a key role for adenosine
receptors in activating human pre-conditioning and
demonstrate the liberation of circulating pre-
conditioning factor(s) by exogenous adenosine.
TRANSLATIONAL OUTLOOK: Future translational
studies should examine the effects of speciﬁc adeno-
sine receptor subtypes to further clarify the physi-
ology of human pre-conditioning and to select
potential drug candidates and doses for future trials.
Studies should also be conducted to ascertain
whether adenosine receptor activation may induce
additive effects to those of mechanical ischemic pre-
conditioning, and if positive, clinically powered ran-
domized controlled trials should be considered in
patients undergoing cardiac surgery or presenting
with acute myocardial infarction.
Contractor et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6
Adenosine in rIPC O C T O B E R 2 0 1 6 : 4 6 1 – 7 1
470individuals is modiﬁed by both their disease pro-
cesses (42) and their drug therapies (43,44). However,
the volunteers in protocol 3 were individuals with
proven or suspected coronary disease undergoing
angiography, and we were nevertheless able to
demonstrate release of cardioprotective factor(s) into
their serum after adenosine infusion, suggesting that
further investigation is warranted.
Despite these limitations, however, not only are
our studies internally consistent in showing that in-
hibition of rIPC by caffeine in the trigger limb is
associated with lack of circulating factor(s), but we
also show that activation of adenosine receptors can
release such factor(s).
CONCLUSIONS
Adenosine receptors activation in the trigger limb
signals rIPC in part through release of circulating
cardioprotective factor(s). This can be reproduced by
arterial infusion of adenosine. The clinical implica-
tions of these ﬁndings to potentially mimic rIPC need
further investigation.
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